Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD

Blood (2010) 116 (21): 1766.

https://doi.org/10.1182/blood.V116.21.1766.1766

Published: 2010

Journal Articles

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Ulrich Jaeger, MD, Otto Krieger, MD, Georg Hopfinger, MD, Cathrin Skrabs, MD, Christine Einberger, Veronika Huter, MD, Hubert Hausmaninger, MD, Johannes Drach, MD, Markus Raderer, MD, Michael Woo, Pharm.D, Helen Melzer, PhD, Richard Greil, MD, Michael A Fridrik, MD

Blood (2008) 112 (11): 1997.

https://doi.org/10.1182/blood.V112.11.1997.1997

Published: 2008

Journal Articles

Individualizing IPSS Risk Assessment in Myelodysplastic Syndromes, by Additionally Taking into Account Age, Gender and French-American-British (FAB) Classification - A Multicenter Analysis.

Thomas Noesslinger, MD, Heinz Tuechler, Ulrich Germing, MD, Peter Valent, Otto Krieger, MD, Detlev Haase, MD, Reinhard Stauder, Michael Pfeilstocker

Blood (2006) 108 (11): 2618.

https://doi.org/10.1182/blood.V108.11.2618.2618

Published: 2006

Journal Articles

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Barbara Hildebrandt, PhD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD, PhD, Norbert Gattermann, MD, PhD, Christa Fonatsch, PhD, Otto Krieger, MD, PhD, Reinhard Stauder, MD, Christian Steidl, MD

Blood (2006) 108 (11): 252.

https://doi.org/10.1182/blood.V108.11.252.252

Published: 2006

Journal Articles

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

Heinz Ludwig, MD, Werner Linkesch, MD, Hedwig Kasparu, MD, Otto Krieger, MD, Ivan Spicka, MD, Gunther Gastl, MD, Richard Greil, MD, Johannes Drach, MD, Josef Thaler, MD, Ingrid Kuhn, Niklas Zojer, MD, Axel Hinke, PhD

Blood (2006) 108 (11): 3083.

https://doi.org/10.1182/blood.V108.11.3083.3083

Published: 2006

Journal Articles

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Thomas Noesslinger, MD, Ulrich Germing, MD, PD, Barbara Hildebrandt, MD, Claudia Strupp, MD, Manuel Aivado, MD, Detlef Haase, MD, Julie Schanz, MD, Friedrich Wimazal, MD, Wolfgang Sperr, MD, Valent Peter, MD, Lubbert Michael, MD, PD, Otto Krieger, MD, Norbert Gattermann, MD, Aristoteles Giagounidis, MD, Heinz Tuchler, Rainer Haas, MD, Carlo Aul, MD, Michael Pfeilstocker, MD, PD

Blood (2004) 104 (11): 1448.

https://doi.org/10.1182/blood.V104.11.1448.1448

Published: 2004

NARROW

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Individualizing IPSS Risk Assessment in Myelodysplastic Syndromes, by Additionally Taking into Account Age, Gender and French-American-British (FAB) Classification - A Multicenter Analysis.

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Email alerts

ASH Publications

American Society of Hematology

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Two-Monthly Rituximab Infusions Maintain Target Concentrations: Pharmacokinetic Data of the AGMT-NHL9 Maintenance Study in Patients with Follicular Lymphoma in Complete or Partial Remission.

Individualizing IPSS Risk Assessment in Myelodysplastic Syndromes, by Additionally Taking into Account Age, Gender and French-American-British (FAB) Classification - A Multicenter Analysis.

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Prospective, Randomized Comparison between Double Transplantation (T) with Melphalan (200 mg/m 2 ) and Triple T with Intermediate Dose Melphalan (100 mg/m 2 ) in Patients with Multiple Myeloma (An Interim Analysis).

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only